Anna Lok News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anna lok. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anna Lok Today - Breaking & Trending Today

No racial disparities observed in chronic HBV treatment rates among eligible patients

Although Black individuals with chronic hepatitis B were less likely to meet treatment criteria, researchers reported no significant differences in treatment initiation between racial groups, according to data in JAMA Network Open.“Because Asians and Blacks have higher prevalence of chronic HBV infection and are more likely to develop liver cancer, we examined whether there are racial ....

United States , Anna Lok , Hepatitisb Research Network , World Health Organization , African American , Michigan Medicine , East Africa , West Africa , North America ,

German scientist, inventor of world's 1st treatment for hepatitis D, chosen for Blumberg Prize by Hepatitis B Foundation - Brazil Business Today

Prof. Stephan Urban led development of the first treatment for hepatitis D, an often-fatal infection for millions of people worldwide. ....

United States , Fox Chase Cancer Center , Baden Wüberg , John Taylor , Baruchs Blumberg , Wolfgang Gerok , Ralf Bartenschlager , Anna Lok , Foundation Distinguished Scholar , Research Award , Centre For Molecular Biology , German Center , Heidelberg University Hospital , Hepatitisb Foundation , Department Of Infectious Diseases , Hepatitis Program , Baruchs Blumberg Institute , Hepatitisb Foundation Gala , University Of Michigan Medical School , Heidelberg University , Stephan Urban , Hepatitisb Foundation President Chari , European Commission , Nobel Prize , Medical Advisory Board , Distinguished Scholar ,

Bulevirtide Shows Real-World Efficacy Versus HDV

French program reveals good cure rates but also a high rate of modifications or discontinuations. ....

Ann Arbor , United States , Anna Lok , European Medicines Agency , French National Agency For Medicines , Drug Administration , Bordeaux France University Hospital , University Of Michigan , Health Products , American Association , Liver Diseases , Victor De Ledinghen , French National Agency , Hepatitis B , Bv Hepatitisb Virus , Biliary Disease , Allbladder Disease , Viral Hepatitis , Liver Disease , Percutaneous Gastrostomy , Clinical Research , Clinical Trials , Linical Studies ,

Be Cautious With HBV Drug Withdrawal

More than half of chronic hepatitis B e antigen–negative patients who withdraw from nucleoside or nucleotide analogue therapy experienced relapse within 4 years. ....

Ann Arbor , United States , Grishma Hirode , Anna Lok , University Of Toronto , University Of Michigan , North America , American Association , Hepatitis B , Bv Hepatitisb Virus , Chronic Hepatitis B , Drug Withdrawal , Transplantation Liver , Epatic Transplantation , Ransplantation Hepatic , Liver Transplantation , Insulin Analog , Insulin Analogue , Biliary Disease , Allbladder Disease , Liver Enzymes , Liver Studies , Liver Disease , Patient Assessment , Patient Evaluation , Atient Mo ,

Target RWE Shares Weight Loss Data From Ongoing NASH Study

Target RWE Shares Weight Loss Data From Ongoing NASH Study
Real-world study shows only 32% of overweight or obese adults with NAFLD in the U.S. achieved 5% or more weight reduction
News provided by
Share this article
DURHAM, N.C., Feb. 2, 2021 /PRNewswire/
Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, shared the latest data from the ongoing TARGET-NASH observational study, published in
The nonalcoholic steatohepatitis (NASH) study,
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort, analyzed 2,019 patients enrolled in the TARGET-NASH cohort in the United States over a median follow-up of 39 months. The baseline characteristics included one third of patients classified as obesity class 2/3, 38.6% of patients had diabetes, and approximately 50% had documentation of lifestyle modifications or diet recommendations. ....

United States , Miguel Malespin , Dan Gagnier Jeffrey Mathews , Anna Lok , Gagnier Communications , University Of Michigan , Transplant Hepatology Specialist , Tampa General Hospital , ஒன்றுபட்டது மாநிலங்களில் , அண்ணா லோக் , பல்கலைக்கழகம் ஆஃப் மிச்சிகன் , மாற்று ஹெபடாலஜி நிபுணர் , தம்பா ஜநரல் மருத்துவமனை ,